Bioequivalence study of Dulotegravir 50 mg tablet
Not Applicable
Recruiting
- Conditions
- This study is performed on healthy volunteers and drug concentration in plasma is determined..
- Registration Number
- IRCT20200105046010N102
- Lead Sponsor
- Sobhan trading group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
General Health (Liver, Heart, and Kidney)
Body Mass Index (18-28)
Informed consent
Age (18-55 years old)
Exclusion Criteria
Smoking
History of cardiovascular disease
History of liver and kidney disease
Alcohol and drug addiction
History of allergy to Dulotegravir
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular targets and mechanisms of action of Dulotegravir in HIV treatment?
How does the bioavailability of Tivimex compare to the originator brand under fed conditions?
Are there specific biomarkers that correlate with plasma drug concentration and efficacy of integrase inhibitors?
What adverse events are commonly associated with integrase strand transfer inhibitors like Dulotegravir in clinical trials?
What are the current combination therapies involving integrase inhibitors and how does Tivimex fit into this landscape?